Applications of circulating tumor cells for prostate cancer

Asian Journal of Urology, 2016, 3 (4): 254-259 doi:

Review

Applications of circulating tumor cells for prostate cancer

Shirley Cheng^a, Jie-Fu Chen^a,b, Yi-Tsung Lu^a,c, Leland W. K. Chung^a,b,d, Hsian-Rong Tseng^e,f, Edwin M. Posadas^a,b,g

a Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA;
b Division of Hematology/Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA;
c Department of Internal Medicine, John H Stroger Hospital, Chicago, IL, USA;
d Cancer Biology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA;
e California Nanosystems Institute, University of California, Los Angeles, CA, USA;
f Department of Molecular Pharmacology, University of California, Los Angeles, CA, USA;
g Translational Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Abstract
Related Citation (15)

Download:

HTML

PDF (1771KB)
Export: BibTeX | EndNote (RIS)

Abstract One of the major challenges that clinicians face is in the difficulties of accurately monitoring disease progression. Prostate cancer is among these diseases and greatly affects the health of men globally. Circulating tumor cells (CTCs) are a rare population of cancer cells that have shed from the primary tumor and entered the peripheral circulation. Not until recently, clinical applications of CTCs have been limited to using enumeration as a prognostic tool in Oncology. However, advances in emerging CTC technologies point toward new applications that could revolutionize the field of prostate cancer. It is now possible to study CTCs as components of a liquid biopsy based on morphological phenotypes, biochemical analyses, and genomic profiling. These advances allow us to gain insight into the heterogeneity and dynamics of cancer biology and to further study the mechanisms behind the evolution of therapeutic resistance. These recent developments utilizing CTCs for clinical applications will greatly impact the future of prostate cancer research and pave the way towards personalized care for men.

Key words： Prostate cancer Circulating tumor cell Biomarker Liquid biopsy Molecular oncology

Received: 31 August 2016 Published: 02 November 2016

	Service
	E-mail this article
	Add to citation manager
	E-mail Alert
	Articles by authors
	Shirley Cheng
	Jie-Fu Chen
	Yi-Tsung Lu
	Leland W. K. Chung
	Hsian-Rong Tseng
	Edwin M. Posadas

TRENDMD:

Cite this article:

Shirley Cheng,Jie-Fu Chen,Yi-Tsung Lu, et al. Applications of circulating tumor cells for prostate cancer[J]. Asian Journal of Urology, 2016, 3(4): 254-259.

URL:

http://www.ajurology.com/EN/ OR http://www.ajurology.com/EN/Y2016/V3/I4/254

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
[2]	You S, Knudsen BS, Erho N, Alshalalfa M, Takhar M, Al-Deen Ashab H, et al. Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome. Cancer Res 2016;76:4948-58.
[3]	Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215-28.
[4]	Zhao SG, Evans JR, Kothari V, Sun G, Larm A, Mondine V, et al. The landscape of prognostic outlier genes in high-risk prostate cancer. Clin Cancer Res 2016;22:1777-86.
[5]	Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer:updated recommendations from the Prostate Cancer clinical trials working group 3. J Clin Oncol 2016; 34:1402-18.
[6]	Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schroder FH, et al. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol 2005;23:6139-48.
[7]	Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G. Prostate cancer clinical trial end points:"RECIST"ing a step backwards. Clin Cancer Res 2005;11:5223-32.
[8]	Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mosquera JM, et al. Challenges in recognizing treatmentrelated neuroendocrine prostate cancer. J Clin Oncol 2012; 30:e386-9.
[9]	Yuan X, Cai C, Chen S, Chen S, Yu Z, Balk SP. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene 2014;33:2815-25.
[10]	Lipianskaya J, Cohen A, Chen CJ, Hsia E, Squires J, Li Z, et al. Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation. Asian J Androl 2014;16:541-4.
[11]	Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LWMM, et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A 1998;95:4589-94.
[12]	Krivacic RT, Ladanyi A, Curry DN, Hsieh HB, Kuhn P, Bergsrud DE, et al. A rare-cell detector for cancer. Proc Natl Acad Sci U S A 2004;101:10501-4.
[13]	Zieglschmid V, Hollmann C, Böcher O. Detection of disseminated tumor cells in peripheral blood. Crit Rev Clin Lab Sci 2005;42:155-96.
[14]	de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-9.
[15]	Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 2014;158:1110-22.
[16]	Chen JF, Ho H, Lichterman J, Lu YT, Zhang Y, Garcia MA, et al. Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases. Cancer 2015;121:3240-51.
[17]	Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, et al. NF-kappaB2/p52 induces resistance to enzalutamide in prostate cancer:role of androgen receptor and its variants. Mol Cancer Ther 2013;12:1629-37.
[18]	Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer:induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011;17:5913-25.
[19]	Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371:1028-38.
[20]	Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, et al. AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC):expanded analysis of the Johns Hopkins cohort. J Clin Oncol 2016;34(suppl; abstr 5012).
[21]	Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castrationresistant prostate cancer. JAMA Oncol 2015;1:582-91.
[22]	Ziaee S, Chu GC, Huang JM, Sieh S, Chung LW. Prostate cancer metastasis:roles of recruitment and reprogramming, cell signal network and three-dimensional growth characteristics. Transl Androl Urol 2015;4:438-54.
[23]	Chu GC, Zhau HE, Wang R, Rogatko A, Feng X, Zayzafoon M, et al. RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. Endocr Relat Cancer 2014;21:311-26.
[24]	Chu GC, Chung LW. RANK-mediated signaling network and cancer metastasis. Cancer Metastasis Rev 2014;33:497-509.
[25]	Tang F, Barbacioru C, Wang Y, Nordman E, Lee C, Xu N, et al. mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods 2009;6:377-82.
[26]	Raj A, van den Bogaard P, Rifkin SA, van Oudenaarden A, Tyagi S. Imaging individual mRNA molecules using multiple singly labeled probes. Nat Methods 2008;5:877-9.
[27]	Klein CA, Seidl S, Petat-Dutter K, Offner S, Geigl JB, SchmidtKittler O, et al. Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol Apr 2002;20:387-92.
[28]	Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science 2015;349:1351-6.
[29]	Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011;472:90-4.
[30]	Xu X, Hou Y, Yin X, Bao L, Tang A, Song L, et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 2012;148:886-95.
[31]	Treff NR, Su J, Tao X, Northrop LE, Scott Jr RT. Single-cell whole-genome amplification technique impacts the accuracy of SNP microarray-based genotyping and copy number analyses. Mol Hum Reprod 2011;17:335-43.
[32]	Magbanua MJ, Sosa EV, Scott JH, Simko J, Collins C, Pinkel D, et al. Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer 2012;12:78.
[33]	Magbanua MJ, Sosa EV, Roy R, Eisenbud LE, Scott JH, Olshen A, et al. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res 2013;73:30-40.
[34]	Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res 2013;73:2965-75.
[35]	Hou S, Zhao L, Shen Q, Yu J, Ng C, Kong X, et al. Polymer nanofiber-embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells. Angew Chem Int Ed Engl 2013;52:3379-83.
[36]	Zhao L, Lu YT, Li F, Wu K, Hou S, Yu J, et al. High-purity prostate circulating tumor cell isolation by a polymer nanofiber-embedded microchip for whole exome sequencing. Adv Mater 2013;25:2897-902.
[37]	Jiang R, Lu YT, Ho H, Li B, Chen JF, Lin M, et al. A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer. Oncotarget 2015;6:44781-93.
[38]	Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P, et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol 2014;32:479-84.
[39]	Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, et al. The evolutionary history of lethal metastatic prostate cancer. Nature 2015;520:353-7.
[40]	Jamal-Hanjani M, Quezada SA, Larkin J, Swanton C. Translational implications of tumor heterogeneity. Clin Cancer Res 2015;21:1258-66.
[41]	Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013;501:338-45.
[42]	Swanton C. Intratumor heterogeneity:evolution through space and time. Cancer Res 2012;72:4875-82.
[43]	Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, EisenbergerMA,etal.Serialblood-basedanalysisofAR-V7inmen withadvancedprostatecancer.AnnOncolSep2015;26:1859-65.
[44]	Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012;44:685-9.